Literature DB >> 10606658

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

P Lorenz1, T Misteli, B F Baker, C F Bennett, D L Spector.   

Abstract

Phosphorothioate oligodeoxynucleotides (P=S ODNs) are frequently used as antisense agents to specifically interfere with the expression of cellular target genes. However, the cell biological properties of P=S ODNs are poorly understood. Here we show that P=S ODNs were able to continuously shuttle between the nucleus and the cytoplasm and that shuttling P=S ODNs retained their ability to act as antisense agents. The shuttling process shares characteristics with active transport since it was inhibited by chilling and ATP depletion in vivo. Transport was carrier-mediated as it was saturable, and nuclear pore complex-mediated as it was sensitive to treatment with wheatgerm agglutinin. Oligonucleotides without a P=S backbone chemistry were only weakly restricted in their migration by chilling, ATP depletion and wheatgerm agglutinin and thus moved by diffusion. P=S ODN shuttling was only moderately affected by disruption of the Ran/RCC1 system. We propose that P=S ODNs shuttle through their binding to yet unidentified cellular molecules that undergo nucleocytoplasmic transport via a pathway that is not as strongly dependent on the Ran/RCC1 system as nuclear export signal-mediated protein export, U-snRNA, tRNA and mRNA export. The shuttling property of P=S ODNs must be taken into account when considering the mode and site of action of these antisense agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606658      PMCID: PMC102511          DOI: 10.1093/nar/28.2.582

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  55 in total

Review 1.  Structure and function of the nuclear pore complex.

Authors:  D J Forbes
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Facilitated nuclear transport of histone H1 and other small nucleophilic proteins.

Authors:  M Breeuwer; D S Goldfarb
Journal:  Cell       Date:  1990-03-23       Impact factor: 41.582

3.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Rapid nuclear accumulation of injected oligodeoxyribonucleotides.

Authors:  D J Chin; G A Green; G Zon; F C Szoka; R M Straubinger
Journal:  New Biol       Date:  1990-12

5.  Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.

Authors:  R W Wagner; M D Matteucci; J G Lewis; A J Gutierrez; C Moulds; B C Froehler
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

6.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Authors:  C F Bennett; M Y Chiang; H Chan; J E Shoemaker; C K Mirabelli
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

7.  Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm.

Authors:  S Piñol-Roma; G Dreyfuss
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

8.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

Authors:  A R Thierry; A Dritschilo
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

9.  Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs.

Authors:  J P Clarenc; B Lebleu; J P Léonetti
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

10.  Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors.

Authors:  S A Adam; R S Marr; L Gerace
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

View more
  32 in total

1.  Visualizing the distribution and transport of mRNAs in living cells.

Authors:  Diana P Bratu; Byeong-Jik Cha; Musa M Mhlanga; Fred Russell Kramer; Sanjay Tyagi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-28       Impact factor: 11.205

Review 2.  Imaging of single mRNAs in the cytoplasm of living cells.

Authors:  Dahlene Fusco; Edouard Bertrand; Robert H Singer
Journal:  Prog Mol Subcell Biol       Date:  2004

3.  Imaging native beta-actin mRNA in motile fibroblasts.

Authors:  Sanjay Tyagi; Osama Alsmadi
Journal:  Biophys J       Date:  2004-09-17       Impact factor: 4.033

4.  Dual FRET molecular beacons for mRNA detection in living cells.

Authors:  Philip J Santangelo; Brent Nix; Andrew Tsourkas; Gang Bao
Journal:  Nucleic Acids Res       Date:  2004-04-14       Impact factor: 16.971

5.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

6.  Uptake, cellular distribution and novel cellular binding proteins of immunostimulatory CpG oligodeoxynucleotides in glioblastoma cells.

Authors:  Zhiren Zhang; Toni Weinschenk; Hermann J Schluesener
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

Review 7.  Antisense approach to inflammatory bowel disease: prospects and challenges.

Authors:  Irene Marafini; Davide Di Fusco; Emma Calabrese; Silvia Sedda; Francesco Pallone; Giovanni Monteleone
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

8.  In vivo colocalisation of oskar mRNA and trans-acting proteins revealed by quantitative imaging of the Drosophila oocyte.

Authors:  Musa M Mhlanga; Diana P Bratu; Auguste Genovesio; Agata Rybarska; Nicolas Chenouard; Ulf Nehrbass; Jean-Christophe Olivo-Marin
Journal:  PLoS One       Date:  2009-07-14       Impact factor: 3.240

Review 9.  Antisense oligonucleotides: treating neurodegeneration at the level of RNA.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 10.  Biological barriers to therapy with antisense and siRNA oligonucleotides.

Authors:  R Juliano; J Bauman; H Kang; X Ming
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.